Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin, type II cytoskeletal 3 (KRT3) is a structural protein that belongs to the type II (basic) cytokeratin family and forms intermediate filaments together with keratin 12 in the corneal epithelium. It plays a critical role in providing resilience and mechanical stability to the outermost layer of the cornea, protecting the eye against mechanical and microbial insults. KRT3 expression is specific to differentiated corneal epithelial cells and is regulated by transcription factors important for ocular surface development. Mutations in the KRT3 gene are causative for Meesmann corneal dystrophy, a disorder characterized by intraepithelial microcyst formation and corneal fragility, but KRT3 itself is not a therapeutic target for drugs[1][2][3][4][5][6].
Not applicable (structural protein, not a common drug target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin, type II cytoskeletal 3 (KRT3).